Search

Your search keyword '"Hayek, Salim"' showing total 1,486 results
Start Over Author "Hayek, Salim"
1,486 results on '"Hayek, Salim"'

1. Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association

Author

Hayek, Salim S, Zaha, Vlad G, Bogle, Carmel, Deswal, Anita, Langston, Amelia, Rotz, Seth, Vasbinder, Alexi, Yang, Eric, Okwuosa, Tochukwu, and Nursing, on behalf of the American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine and the Council on Cardiovascular and Stroke

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Heart Disease, Hematology, Cancer, Cardiovascular, Pediatric, Stem Cell Research - Nonembryonic - Human, Aging, Regenerative Medicine, Stem Cell Research, Clinical Research, Patient Safety, Transplantation, Prevention, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Adult, Humans, Child, Aged, Cardiovascular Diseases, Survivorship, American Heart Association, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Heart Diseases, AHA Scientific Statements, arrhythmias, cardiac, atherosclerosis, bone marrow transplantation, heart failure, risk assessment, American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, and the Council on Cardiovascular and Stroke Nursing, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences, Sports science and exercise
Abstract

Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell transplantation consists of 4 phases: pretransplantation workup, conditioning therapy and infusion, immediate posttransplantation period, and long-term survivorship. Complications can occur during each phase, with long-term survivors facing increased risks for late effects such as cardiovascular disease, secondary malignancies, and endocrinopathies. In adults, arrhythmias such as atrial fibrillation and flutter are the most frequent acute cardiovascular complication. Acute heart failure has an incidence ranging from 0.4% to 2.2%. In pediatric patients, left ventricular systolic dysfunction and pericardial effusion are the most common cardiovascular complications. Factors influencing the incidence and risk of complications include pretransplantation therapies, transplantation type (autologous versus allogeneic), conditioning regimen, comorbid conditions, and patient age. The pretransplantation cardiovascular evaluation consists of 4 steps: (1) initial risk stratification, (2) exclusion of high-risk cardiovascular disease, (3) assessment of cardiac reserve, and (4) optimization of cardiovascular reserve. Clinical risk scores could be useful tools for the risk stratification of adult patients. Long-term cardiovascular management of hematopoietic stem cell transplantation survivors includes optimizing risk factors, monitoring, and maintaining a low threshold for evaluating cardiovascular causes of symptoms. Future research should prioritize refining risk stratification and creating evidence-based guidelines and strategies to optimize outcomes in this growing patient population.

Published
2024

2. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.

Author

Lehmann, Lorenz, Heckmann, Markus, Bailly, Guillaume, Finke, Daniel, Procureur, Adrien, Power, John, Stein, Frederic, Bretagne, Marie, Ederhy, Stephane, Fenioux, Charlotte, Hamwy, Omar, Funck-Brentano, Elisa, Romano, Emanuela, Pieroni, Laurence, Münster, Jan, Allenbach, Yves, Anquetil, Céline, Leonard-Louis, Sarah, Palaskas, Nicolas, Hayek, Salim, Katus, Hugo, Giannitsis, Evangelos, Frey, Norbert, Kaya, Ziya, Moslehi, Javid, Prifti, Edi, and Salem, Joe-Elie

Subjects
biomarkers, drug-related side effects and adverse reactions, immune checkpoint inhibitors, myocarditis, pharmacology, troponins, Humans, Myocarditis, Immune Checkpoint Inhibitors, Biomarkers, Creatine Kinase, Prognosis, Troponin T
Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established. METHODS: We analyzed the diagnostic accuracy and prognostic performances of cTnI, cTnT, and CK in patients with ICI myocarditis (n=60) through 1-year follow-up in 2 cardio-oncology units (APHP Sorbonne, Paris, France and Heidelberg, Germany). A total of 1751 (1 cTnT assay type), 920 (4 cTnI assay types), and 1191 CK sampling time points were available. Major adverse cardiomyotoxic events (MACE) were defined as heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring pacemaker, respiratory muscle failure requiring mechanical ventilation, and sudden cardiac death. Diagnostic performance of cTnI and cTnT was also assessed in an international ICI myocarditis registry. RESULTS: Within 72 hours of admission, cTnT, cTnI, and CK were increased compared with upper reference limits (URLs) in 56 of 57 (98%), 37 of 42 ([88%] P=0.03 versus cTnT), and 43 of 57 ([75%] P

Published
2023

3. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

4. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2023
Full Text
View/download PDF

6. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*

Author

Chalkias, Athanasios, Huang, Yiyuan, Ismail, Anis, Pantazopoulos, Ioannis, Papagiannakis, Nikolaos, Bitterman, Brayden, Anderson, Elizabeth, Catalan, Tonimarie, Erne, Grace K., Tilley, Caroline R., Alaka, Abiola, Amadi, Kingsley M., Presswalla, Feriel, Blakely, Pennelope, Bernal-Morell, Enrique, Cebreiros López, Iria, Eugen-Olsen, Jesper, García de Guadiana Romualdo, Luis, Giamarellos-Bourboulis, Evangelos J., Loosen, Sven H., Reiser, Jochen, Tacke, Frank, Skoulakis, Anargyros, Laou, Eleni, Banerjee, Mousumi, Pop-Busui, Rodica, Hayek, Salim S., Hayek, Salim S., Blakely, Pennelope, Launius, Christopher, Berlin, Hanna, Amadi, Kingsley M., Azam, Tariq U., Shadid, Husam, Pan, Michael, O’ Hayer, Patrick, Meloche, Chelsea, Feroze, Rafey, Padalia, Kishan J., Anderson, Elizabeth, Perry, Danny, Bitar, Abbas, Kaakati, Rayan, Zhao, Lili, Zhao, Peiyao, Michaud, Erinleigh, Huang, Yiyuan, Catalan, Tonimarie, Khaleel, Ibrahim, Alaka, Abiola, Pop-Busui, Rodica, Banerjee, Mousumi, Tekumulla, Annika, Tilley, Caroline R., Tripathi, Medha, Vasbinder, Alexi, Bardwell, Alina, Presswalla, Feriel, Nelapudi, Namratha, Erne, Grace K., Chen, Jiazi, Mayette, Nathan, Sulaiman, Noor, Ismail, Anis, Pizzo, Ian, Bitterman, Brayden, Reiser, Jochen, Samelko, Beata, Hlepas, Alexander, Wang, Xuexiang, Patel, Priya, Chalkias, Athanasios, Pantazopoulos, Ioannis, Laou, Eleni, Skoulakis, Anargyros, Papagiannakis, Nikolaos, Eugen-Olsen, Jesper, Altintas, Izzet, Tingleff, Jens, Stauning, Marius, Houlind, Morten Baltzer, Lindstrøm, Mette B, Andersen, Ove, Gamst-Jensen, Hejdi, Hartmann Rasmussen, Line Jee, Rasmussen, Christian, Nehlin, Jan O., Kallemose, Thomas, Parvaiz, Imran, Loosen, Sven H., Luedde, Tom, Keitel, Verena, Giamarellos-Bourboulis, Evangelos J., Adami, Maria-Evangelia, Solomonidi, Nicky, Tsilika, Maria, Saridaki, Maria, Lekakis, Vasileios, Tacke, Frank, Tober-Lau, Pinkus, Mohr, Raphael, Kurth, Florian, Sander, Leif Erik, Jochum, Christoph, Garcia de Guadiana-Romualdo, Luis, Albaladejo-Otón, María Dolores, Rodríguez Mulero, María Dolores, Martínez, María Galindo, Olivo, Marta Hernández, Rodríguez, Valerio Campos, López, Iria Cebreiros, Carrillo, María Arnaldos, Noguera Velasco, Jose Antonio, Pascual Figal, Domingo A., Morell, Enrique Bernal, García, Antonia Alcaraz, Alcaraz García, María José, Martínez, Monica Martínez, Esteban-Torrella, Patricia, and Sancho-Rodríguez, Natalia

Published
2024
Full Text
View/download PDF

7. Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States.

Author

Ganatra, Sarju, Dani, Sourbha S, Kumar, Ashish, Khan, Safi U, Wadhera, Rishi, Neilan, Tomas G, Thavendiranathan, Paaladinesh, Barac, Ana, Hermann, Joerg, Leja, Monika, Deswal, Anita, Fradley, Michael, Liu, Jennifer E, Sadler, Diego, Asnani, Aarti, Baldassarre, Lauren A, Gupta, Dipti, Yang, Eric, Guha, Avirup, Brown, Sherry-Ann, Stevens, Jennifer, Hayek, Salim S, Porter, Charles, Kalra, Ankur, Baron, Suzanne J, Ky, Bonnie, Virani, Salim S, Kazi, Dhruv, Nasir, Khurram, and Nohria, Anju

Abstract

Racial and social disparities exist in outcomes related to cancer and cardiovascular disease (CVD).The aim of this cross-sectional study was to study the impact of social vulnerability on mortality attributed to comorbid cancer and CVD.The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database (2015-2019) was used to obtain county-level mortality data attributed to cancer, CVD, and comorbid cancer and CVD. County-level social vulnerability index (SVI) data (2014-2018) were obtained from the CDC's Agency for Toxic Substances and Disease Registry. SVI percentiles were generated for each county and aggregated to form SVI quartiles. Age-adjusted mortality rates (AAMRs) were estimated and compared across SVI quartiles to assess the impact of social vulnerability on mortality related to cancer, CVD, and comorbid cancer and CVD.The AAMR for comorbid cancer and CVD was 47.75 (95% CI: 47.66-47.85) per 100,000 person-years, with higher mortality in counties with greater social vulnerability. AAMRs for cancer and CVD were also significantly greater in counties with the highest SVIs. However, the proportional increase in mortality between the highest and lowest SVI counties was greater for comorbid cancer and CVD than for either cancer or CVD alone. Adults

Published
2022

8. Particulate Matter 2.5 Pollution Impact on Comorbid Cancer and Cardiovascular Disease Mortality in the U.S.

Author

Kumar, Ashish, Khadke, Sumanth, AlKindi, Sadeer, Rajagopalan, Sanjay, Nasir, Khurram, Kazi, Dhruv, Ahmad, Javaria, Khan, Safi, Asnani, Aarti, Addison, Daniel, Sadler, Diego, Deswal, Anita, Barac, Ana, Guha, Avirup, Liu, Jennifer, Lenihan, Daniel, Neilan, Tomas G., Hayek, Salim, Hermann, Joerg, Nohria, Anju, Dani, Sourbha S., and Ganatra, Sarju

Published
2024
Full Text
View/download PDF

9. The Neurostimulation Appropriateness Consensus Committee (NACC)®: Recommendations for the Mitigation of Complications of Neurostimulation

Author

Deer, Timothy R., Russo, Marc A., Sayed, Dawood, Pope, Jason E., Grider, Jay S., Hagedorn, Jonathan M., Falowski, Steven M., Al-Kaisy, Adnan, Slavin, Konstantin V., Li, Sean, Poree, Lawrence R., Eldabe, Sam, Meier, Kaare, Lamer, Tim J., Pilitsis, Julie G., De Andrés, Jose, Perruchoud, Christophe, Carayannopoulos, Alexios G., Moeschler, Susan M., Hadanny, Amir, Lee, Eric, Varshney, Vishal P., Desai, Mehul J., Pahapill, Peter, Osborn, J., Bojanic, Stana, Antony, Ajay, Piedimonte, Fabian, Hayek, Salim M., and Levy, Robert M.

Published
2024
Full Text
View/download PDF

10. The Neurostimulation Appropriateness Consensus Committee (NACC)®: Recommendations for Spinal Cord Stimulation Long-Term Outcome Optimization and Salvage Therapy

Author

Deer, Timothy R., Russo, Marc, Grider, Jay S., Sayed, Dawood, Lamer, Tim J., Dickerson, David M., Hagedorn, Jonathan M., Petersen, Erika A., Fishman, Michael A., FitzGerald, James, Baranidharan, Ganesan, De Ridder, Dirk, Chakravarthy, Krishnan V., Al-Kaisy, Adnan, Hunter, Corey W., Buchser, Eric, Chapman, Kenneth, Gilligan, Chris, Hayek, Salim M., Thomson, Simon, Strand, Natalie, Jameson, Jessica, Simopoulos, Thomas T., Yang, Ajax, De Coster, Olivier, Cremaschi, Fabián, Christo, Paul J., Varshney, Vishal, Bojanic, Stana, and Levy, Robert M.

Published
2024
Full Text
View/download PDF

16. Five-Year Longitudinal Follow-Up of Restorative Neurostimulation Shows Durability of Effectiveness in Patients With Refractory Chronic Low Back Pain Associated With Multifidus Muscle Dysfunction

Author

Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Sayed, Dawood, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean-Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Maislin, Greg, Heemels, Jan Pieter, and Eldabe, Sam

Published
2024
Full Text
View/download PDF

18. Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2024
Full Text
View/download PDF

20. Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry.

Author

Tehrani, David M, Wang, Xiaoyan, Rafique, Asim M, Hayek, Salim S, Herrmann, Joerg, Neilan, Tomas G, Desai, Pooja, Morgans, Alicia, Lopez-Mattei, Juan, Parikh, Rushi V, and Yang, Eric H

Abstract

While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. The purpose of this study is to evaluate the effect of underlying CVD and CVD risk factors with cancer history on in-hospital mortality in those with COVID-19.Data from symptomatic adults hospitalized with COVID-19 at 86 hospitals in the US enrolled in the American Heart Association's COVID-19 CVD Registry was analyzed. The primary exposure was cancer history. The primary outcome was in-hospital death. Multivariable logistic regression models were adjusted for demographics, CVD risk factors, and CVD. Interaction between history of cancer with concomitant CVD and CVD risk factors were tested.Among 8222 patients, 892 (10.8%) had a history of cancer and 1501 (18.3%) died. Cancer history had significant interaction with CVD risk factors of age, body mass index (BMI), and smoking history, but not underlying CVD itself. History of cancer was significantly associated with increased in-hospital death (among average age and BMI patients, adjusted odds ratio [aOR] = 3.60, 95% confidence interval [CI]: 2.07-6.24; p

Published
2021

21. Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019.

Author

Churpek, Matthew, Gupta, Shruti, Spicer, Alexandra, Hayek, Salim, Srivastava, Anand, Chan, Lili, Melamed, Michal, Brenner, Samantha, Radbel, Jared, Madhani-Lovely, Farah, Bhatraju, Pavan, Bansal, Anip, Green, Adam, Goyal, Nitender, Shaefi, Shahzad, Parikh, Chirag, Semler, Matthew, and Leaf, David

Subjects
artificial intelligence, coronavirus disease 2019, intensive care unit, machine learning
Abstract

OBJECTIVES: Critically ill patients with coronavirus disease 2019 have variable mortality. Risk scores could improve care and be used for prognostic enrichment in trials. We aimed to compare machine learning algorithms and develop a simple tool for predicting 28-day mortality in ICU patients with coronavirus disease 2019. DESIGN: This was an observational study of adult patients with coronavirus disease 2019. The primary outcome was 28-day inhospital mortality. Machine learning models and a simple tool were derived using variables from the first 48 hours of ICU admission and validated externally in independent sites and temporally with more recent admissions. Models were compared with a modified Sequential Organ Failure Assessment score, National Early Warning Score, and CURB-65 using the area under the receiver operating characteristic curve and calibration. SETTING: Sixty-eight U.S. ICUs. PATIENTS: Adults with coronavirus disease 2019 admitted to 68 ICUs in the United States between March 4, 2020, and June 29, 2020. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The study included 5,075 patients, 1,846 (36.4%) of whom died by day 28. eXtreme Gradient Boosting had the highest area under the receiver operating characteristic curve in external validation (0.81) and was well-calibrated, while k-nearest neighbors were the lowest performing machine learning algorithm (area under the receiver operating characteristic curve 0.69). Findings were similar with temporal validation. The simple tool, which was created using the most important features from the eXtreme Gradient Boosting model, had a significantly higher area under the receiver operating characteristic curve in external validation (0.78) than the Sequential Organ Failure Assessment score (0.69), National Early Warning Score (0.60), and CURB-65 (0.65; p < 0.05 for all comparisons). Age, number of ICU beds, creatinine, lactate, arterial pH, and Pao2/Fio2 ratio were the most important predictors in the eXtreme Gradient Boosting model. CONCLUSIONS: eXtreme Gradient Boosting had the highest discrimination overall, and our simple tool had higher discrimination than a modified Sequential Organ Failure Assessment score, National Early Warning Score, and CURB-65 on external validation. These models could be used to improve triage decisions and clinical trial enrichment.

Published
2021

22. The Polyanalgesic Consensus Conference (PACC)®: Updates on Clinical Pharmacology and Comorbidity Management in Intrathecal Drug Delivery for Cancer Pain

Author

Deer, Timothy R., Hayek, Salim M., Grider, Jay S., Pope, Jason E., Brogan, Shane E., Gulati, Amitabh, Hagedorn, Jonathan M., Strand, Natalie, Hah, Jennifer, Yaksh, Tony L., Staats, Peter S., Perruchoud, Christophe, Knezevic, Nebojsa Nick, Wallace, Mark S., Pilitsis, Julie G., Lamer, Tim J., Buchser, Eric, Varshney, Vishal, Osborn, Jill, Goel, Vasudha, Simpson, Brian A., Lopez, Jose A., Dupoiron, Denis, Saulino, Michael F., McDowell, Gladstone C., II, Piedimonte, Fabian, and Levy, Robert M.

Published
2024
Full Text
View/download PDF

24. Achievement of LDL-C

Author

Navar, Ann Marie, Shah, Nishant P., Shrader, Peter, Thomas, Laine E., Ahmad, Zahid, Allred, Clint, Chamberlain, Alanna M., Chrischilles, Elizabeth A., Dhalwani, Nafeesa, Effron, Mark B., Hayek, Salim, Jones, Laney K., Kalich, Bethany, Shapiro, Michael D., Wójcik, Cezary, and Peterson, Eric D.

Published
2024
Full Text
View/download PDF

25. Cardiovascular and Thromboembolic Events in Children and Adults With Glomerular Disease: Findings From the Cure GlomeruloNephropathy (CureGN) Network

Author

Wadhwani, Shikha, Mansfield, Sarah A., Smith, Abigail R., Robinson, Bruce M., Abdelghani, Eman, Al-Uzri, Amira, Ashoor, Isa F., Bartosh, Sharon M., Chishti, Aftab S., Hayek, Salim S., Hladunewich, Michelle A., Kerlin, Bryce A., Madapoosi, Siddharth S., Mariani, Laura H., Mottl, Amy K., Rheault, Michelle N., O’Shaughnessy, Michelle M., Sperati, C. John, Srivastava, Tarak, Selewski, David T., Wang, Chia-shi, Wong, Craig S., Weaver, Donald J., Jr., and Khalid, Myda

Published
2024
Full Text
View/download PDF

27. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

Author

Vasbinder, Alexi, Hoeger, Christopher W., Catalan, Tonimarie, Anderson, Elizabeth, Chu, Catherine, Kotzin, Megan, Xie, Jeffrey, Kaakati, Rayan, Berlin, Hanna P., Shadid, Husam, Perry, Daniel, Pan, Michael, Takiar, Radhika, Padalia, Kishan, Mills, Jamie, Meloche, Chelsea, Bardwell, Alina, Rochlen, Matthew, Blakely, Pennelope, Leja, Monika, Banerjee, Mousumi, Riwes, Mary, Magenau, John, Anand, Sarah, Ghosh, Monalisa, Pawarode, Attaphol, Yanik, Gregory, Nathan, Sunita, Maciejewski, John, Okwuosa, Tochukwu, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

28. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19.

Author

Shaefi, Shahzad, Brenner, Samantha, Gupta, Shruti, OGara, Brian, Krajewski, Megan, Charytan, David, Chaudhry, Sobaata, Mirza, Sara, Peev, Vasil, Anderson, Mark, Bansal, Anip, Hayek, Salim, Srivastava, Anand, Mathews, Kusum, Johns, Tanya, Leonberg-Yoo, Amanda, Green, Adam, Arunthamakun, Justin, Wille, Keith, Shaukat, Tanveer, Singh, Harkarandeep, Admon, Andrew, Semler, Matthew, Hernán, Miguel, Mueller, Ariel, Wang, Wei, and Leaf, David

Subjects
ARDS, COVID-19, Extracorporeal membrane oxygenation, Mortality, Severe respiratory failure, VV-ECMO, Adult, COVID-19, Cohort Studies, Extracorporeal Membrane Oxygenation, Female, Humans, Male, Middle Aged, Respiratory Distress Syndrome, Treatment Outcome
Abstract

PURPOSE: Limited data are available on venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe hypoxemic respiratory failure from coronavirus disease 2019 (COVID-19). METHODS: We examined the clinical features and outcomes of 190 patients treated with ECMO within 14 days of ICU admission, using data from a multicenter cohort study of 5122 critically ill adults with COVID-19 admitted to 68 hospitals across the United States. To estimate the effect of ECMO on mortality, we emulated a target trial of ECMO receipt versus no ECMO receipt within 7 days of ICU admission among mechanically ventilated patients with severe hypoxemia (PaO2/FiO2

Published
2021

29. Aggregate Clinical and Biomarker-Based Model Predicts Adverse Outcomes in Patients With Coronary Artery Disease

Author

Desai, Shivang R., Dhindsa, Devinder S., Ko, Yi-An, Sandesara, Pratik B., Mehta, Anurag, Liu, Chang, Tahhan, Ayman S., Hayek, Salim S., Ejaz, Kiran, Hooda, Ananya, Alkhoder, Ayman, Islam, Shabatun J., Rogers, Steven C., Beshiri, Agim, Murtagh, Gillian, Kim, Jonathan H., Wilson, Peter, Almuwaqqat, Zakaria, Sperling, Laurence S., and Quyyumi, Arshed A.

Published
2023
Full Text
View/download PDF

30. Abstract 15850: Low Rates of Achievement of Low-Density Lipoprotein Cholesterol Levels <55 mg/dL Among Patients With Atherosclerotic Cardiovascular Disease in the United States: Findings From the Cardiovascular Multicenter Observational Investigation of Lipid Care in the United States-2 Registry

Author

Navar, Ann Marie, Shah, Nishant, Shrader, Peter, Thomas, Laine E, Ahmad, Zahid, Allred, Clint, Chamberlain, Alanna M, Chrischilles, Elizabeth A, Dhalwani, Nafeesa, Effron, Mark B, Hayek, Salim, Jones, Laney K, Kalich, Bethany, Shapiro, Michael D, Wojcik, Cezary, and Peterson, Eric D

Published
2023
Full Text
View/download PDF

31. Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Boussouar, Samia, Bretagne, Marie, Power, John R., Moslehi, Javid J., Gougis, Paul, Amelin, Damien, Dechartres, Agnès, Lehmann, Lorenz H., Courand, Pierre-Yves, Cautela, Jennifer, Alexandre, Joachim, Procureur, Adrien, Rozes, Antoine, Leonard-Louis, Sarah, Qin, Juan, Cheynier, Rémi, Charmeteau-De Muylder, Benedicte, Redheuil, Alban, Tubach, Florence, Cadranel, Jacques, Milon, Audrey, Ederhy, Stéphane, Similowski, Thomas, Johnson, Douglas B., Pizzo, Ian, Catalan, Toniemarie, Benveniste, Olivier, Hayek, Salim S., Allenbach, Yves, Rosenzwajg, Michelle, Dolladille, Charles, and Salem, Joe-Elie

Published
2023
Full Text
View/download PDF

33. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.

Author

Ganatra, Sarju, Carver, Joseph R, Hayek, Salim S, Ky, Bonnie, Leja, Monika J, Lenihan, Daniel J, Lenneman, Carrie, Mousavi, Negaresh, Park, Jae H, Perales, Miguel Angel, Ryan, Thomas D, Scherrer-Crosbie, Marielle, Steingart, Richard M, Yang, Eric H, Zaha, Vlad, Barac, Ana, and Liu, Jennifer E

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as a therapeutic option of other malignancies. The main adverse effect of CAR T-cell therapy is potentially life-threatening cytokine release syndrome (CRS). Clinical cardiovascular (CV) manifestations of CRS include tachycardia, hypotension, troponin elevation, reduced left ventricular ejection fraction, pulmonary edema, and cardiogenic shock. Although insults related to CRS toxicity might be transient and reversible in most instances in patients with adequate CV reserve, they can be particularly challenging in higher-risk, often elderly patients with pre-existing CV disease. As the use of CAR T-cell therapy expands to include a wider patient population, careful patient selection, pre-treatment cardiac evaluation, and CV risk stratification should be considered within the CAR T-cell treatment protocol. Early diagnosis and management of CV complications in patients with CRS require awareness and multidisciplinary collaboration.

Published
2019

38. Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction

Author

Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Sayed, Dawood, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean-Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Schwab, Frank, Maislin, Greg, Heemels, Jan Pieter, and Eldabe, Sam

Published
2023
Full Text
View/download PDF

39. Long-Term Outcomes of Restorative Neurostimulation in Patients With Refractory Chronic Low Back Pain Secondary to Multifidus Dysfunction: Two-Year Results of the ReActiv8-B Pivotal Trial

Author

Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean-Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Maislin, Greg, Heemels, Jan Pieter, and Eldabe, Sam

Published
2023
Full Text
View/download PDF

40. Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD

Author

Eckardt, Kai-Uwe, Meiselbach, Heike, Schneider, Markus P., Schiffer, Mario, Prokosch, Hans-Ulrich, Bärthlein, Barbara, Beck, Andreas, Kraska, Detlef, Reis, André, Ekici, Arif B., Becker, Susanne, Alberth-Schmidt, Ulrike, Marschall, Sabine, Schefler, Eugenia, Weigel, Anke, Walz, Gerd, Köttgen, Anna, Schultheiß, Ulla T., Kotsis, Fruzsina, Meder, Simone, Mitsch, Erna, Reinhard, Ursula, Floege, Jürgen, Saritas, Turgay, Schaeffner, Elke, Baid-Agrawal, Seema, Theisen, Kerstin, Schmidt-Ott, Kai, Zeier, Martin, Sommerer, Claudia, Aykac, Mehtap, Wolf, Gunter, Busch, Martin, Paul, Rainer, Sitter, Thomas, Wanner, Christoph, Krane, Vera, Börner-Klein, Antje, Bauer, Britta, Kronenberg, Florian, Raschenberger, Julia, Kollerits, Barbara, Forer, Lukas, Schönherr, Sebastian, Weissensteiner, Hansi, Oefner, Peter, Gronwald, Wolfram, Schmid, Matthias, Nadal, Jennifer, Müller-Krebs, Sandra, Schultheiss, Ulla T., Friedrich, Nele, Nauck, Matthias, Nußhag, Christian, Reiser, Jochen, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

41. Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019

Author

O'Hayer, Patrick J, Vasbinder, Alexi, Anderson, Elizabeth, Catalan, Tonimarie, Bitterman, Brayden, Khaleel, Ibrahim, Erne, Grace, Tekumulla, Annika, Tilley, Caroline, Presswalla, Feriel, Nelapudi, Namratha, Chen, Jiazi, Tripathi, Medha, Rochlen, Matthew, Rambo, Loni, Sulaiman, Noor, Blakely, Pennelope, Huang, Yiyuan, Zhao, Lili, Pop-Busui, Rodica, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

42. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

Author

Aghel, Nazanin, Alexandre, Joachim, Aonuma, Kazutaka, Asnani, Aarti H., Behling, Juliane, Bilen, Mehmet, Bottinor, Wendy, Cariou, Eve, Chahine, Johnny, Chan, Weiting, Chauhan, Aman, Cohen, Max, Crusz, Shanthini, Fernando, Suran, Florido, Roberta, Frigeri, Mauro, Fukushima, Satoshi, Gaughan, Elizabeth, Geisler, Benjamin P., Gilstrap, Lauren, Grohe, Christian, Guha, Avirup, Habib, Manhal, Haegler-Laube, Eva, Haydon, Andrew, Hayek, Salim, Hughes, Andrew, Imai, Rysk, Katsume, Yumi, Kimura, Hideki, Koo Lin, Lily, Lenneman, Carrie, Leong, Daryl, Makker, Vicky, Martinez-Calle, Nicolas, Moey, Melissa, Mohri, Masahiro, Morimoto, Ryota, Moritoki, Yoshinobu, Narezkina, Anna, Nicol, Martin, Nooka, Ajay, Orimoloye, Olusola, Patel, Milan, Perl, Michal, Piriou, Nicolas, Raikhelkar, Jayant K., Raza, Yasmin, Rao, Anjali, Reddy, Sunil, Seki, Nobuhiko, Stangl, Karl, Stewart, Andrew, Stringer, Bryan, Tamarappoo, Balaji K., Tamura, Yuichi, Thuny, Frank, Tierney, Sean, Tresorier, Romain, Ullah, Waqas, Von Hunolstein, Jean-Jacques, Warner, Ellen, Weppler, Allison, Nowatzke, Joseph, Guedeney, Paul, Palaskas, Nicholas, Lehmann, Lorenz, Ederhy, Stephane, Zhu, Han, Cautela, Jennifer, Francis, Sanjeev, Courand, Pierre-Yves, Deswal, Anita, Ewer, Steven M., Aras, Mandar, Arangalage, Dimitri, Ghafourian, Kambiz, Fenioux, Charlotte, Finke, Daniel, Peretto, Giovanni, Zaha, Vlad, Itzhaki Ben Zadok, Osnat, Tajiri, Kazuko, Akhter, Nausheen, Levenson, Joshua, Baldassarre, Lauren, Power, John, Huang, Shi, Collet, Jean-Philippe, Moslehi, Javid, and Salem, Joe-Elie

Published
2022
Full Text
View/download PDF

43. Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis

Author

Vasbinder, Alexi, Chen, YeeAnn, Procureur, Adrien, Gradone, Allison, Azam, Tariq U., Perry, Daniel, Shadid, Husam, Anderson, Elizabeth, Catalan, Tonimarie, Blakely, Pennelope, Nelapudi, Namratha, Fardous, Mohamad, Bretagne, Marie C., Adie, Sarah K., Pogue, Kristen T., Leja, Monika, Yentz, Sarah, Schneider, Bryan, Fecher, Leslie A., Lao, Christopher D., Salem, Joe-Elie, and Hayek, Salim S.

Published
2022
Full Text
View/download PDF

45. Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week.

Author

Hayek, Salim S, Ganatra, Sarju, Lenneman, Carrie, Scherrer-Crosbie, Marielle, Leja, Monika, Lenihan, Daniel J, Yang, Eric, Ryan, Thomas D, Liu, Jennifer, Carver, Joseph, Mousavi, Negareh, O'Quinn, Rupal, Arnold, Anita, Banchs, Jose, Barac, Ana, and Ky, Bonnie

Abstract

Cardiovascular disease and cancer are the 2 main causes of death in the United States. They intersect on multiple levels, sharing common causal mechanisms and epidemiological risk factors. The growing prevalence and complexity of cardiovascular disease and cancer have resulted in the development of the discipline of cardio-oncology. Preparing the cardiovascular workforce for the care of a growing population of cancer patients is necessary to enhance the delivery of high-quality cardiovascular care for patients with cancer. The goal of this review is to present the dedicated efforts of the cardio-oncology community to meet the growing need for education and training of cardiovascular practitioners providing care to cancer patients and survivors. Integration in general cardiology training programs and the efforts of the stakeholder organizations serve as an example of how a multidimensional, innovative approach can address provider education and training needs in a relatively new discipline.

Published
2019

46. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Author

Heidenreich, Paul A., Bozkurt, Biykem, Aguilar, David, Allen, Larry A., Byun, Joni J., Colvin, Monica M., Deswal, Anita, Drazner, Mark H., Dunlay, Shannon M., Evers, Linda R., Fang, James C., Fedson, Savitri E., Fonarow, Gregg C., Hayek, Salim S., Hernandez, Adrian F., Khazanie, Prateeti, Kittleson, Michelle M., Lee, Christopher S., Link, Mark S., Milano, Carmelo A., Nnacheta, Lorraine C., Sandhu, Alexander T., Stevenson, Lynne Warner, Vardeny, Orly, Vest, Amanda R., and Yancy, Clyde W.

Published
2022
Full Text
View/download PDF

47. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Author

Heidenreich, Paul A., Bozkurt, Biykem, Aguilar, David, Allen, Larry A., Byun, Joni J., Colvin, Monica M., Deswal, Anita, Drazner, Mark H., Dunlay, Shannon M., Evers, Linda R., Fang, James C., Fedson, Savitri E., Fonarow, Gregg C., Hayek, Salim S., Hernandez, Adrian F., Khazanie, Prateeti, Kittleson, Michelle M., Lee, Christopher S., Link, Mark S., Milano, Carmelo A., Nnacheta, Lorraine C., Sandhu, Alexander T., Stevenson, Lynne Warner, Vardeny, Orly, Vest, Amanda R., and Yancy, Clyde W.

Published
2022
Full Text
View/download PDF

48. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary

Author

Heidenreich, PAUL A., BOZKURT, BIYKEM, AGUILAR, DAVID, ALLEN, LARRY A., BYUN, JONI-J., COLVIN, MONICA M., DESWAL, ANITA, DRAZNER, MARK H., DUNLAY, SHANNON M., EVERS, LINDA R., FANG, JAMES C., FEDSON, SAVITRI E., FONAROW, GREGG C., HAYEK, SALIM S., HERNANDEZ, ADRIAN F., KHAZANIE, PRATEETI, KITTLESON, MICHELLE M., LEE, CHRISTOPHER S., LINK, MARK S., MILANO, CARMELO A., NNACHETA, LORRAINE C., SANDHU, ALEXANDER T., STEVENSON, LYNNE WARNER, VARDENY, ORLY, VEST, AMANDA R., and YANCY, CLYDE W.

Published
2022
Full Text
View/download PDF

49. Molecular consequences of SARS-CoV-2 liver tropism

Author

Wanner, Nicola, Andrieux, Geoffroy, Badia-i-Mompel, Pau, Edler, Carolin, Pfefferle, Susanne, Lindenmeyer, Maja T., Schmidt-Lauber, Christian, Czogalla, Jan, Wong, Milagros N., Okabayashi, Yusuke, Braun, Fabian, Lütgehetmann, Marc, Meister, Elisabeth, Lu, Shun, Noriega, Maria L. M., Günther, Thomas, Grundhoff, Adam, Fischer, Nicole, Bräuninger, Hanna, Lindner, Diana, Westermann, Dirk, Haas, Fabian, Roedl, Kevin, Kluge, Stefan, Addo, Marylyn M., Huber, Samuel, Lohse, Ansgar W., Reiser, Jochen, Ondruschka, Benjamin, Sperhake, Jan P., Saez-Rodriguez, Julio, Boerries, Melanie, Hayek, Salim S., Aepfelbacher, Martin, Scaturro, Pietro, Puelles, Victor G., and Huber, Tobias B.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results